Activity of the company:
- Investments in the development of safe new generation drugs
- Investments in IT technologies
- Investments in innovative developments
- Development of our own products
“Someone is sitting in the shade today because
someone planted a tree a long time ago“
Investment company United Financial Group is the trust management of Investment Capital. Formation and management of assets included in the company's investment portfolio.
Total number of investment shares:
2 400 000
The number of
Profit is distributed to investment shares
The company's investment portfolio includes the most promising industries and technologies, such as safe medicine and it developments in the field of blockchain technologies.
Investments in a promising business with a turnover of more than $ 200 billion dollars a year
An opportunity to have access to all preparations and company developments at the lowest prices
The annual payment of dividends to investors of the company, after calculating the annual profit
The ability to transfer their shares in the company by inheritance
Participation in the creation of an important area in the safe therapy and treatment of many diseases
Profit from all development and investment tools of the company
in 2010, the company's share was worth $ 0.009, and after 9 years the price rose to $ 44 per share. An investment of $ 100 in Uber, after 9 years made a profit of $ 500,000
The company was founded in 1996. Initial investment in the company amounted to $ 25 million. The current capitalization of the company is about 1 trillion dollars. An investment of $ 100 in 1998 grew to $ 4,000,000 after 20 years.
Steve Jobs, Steve Wozniak, and Ron Wayne founded the company in 1976. Ron Wayne sold his 10% stake for $ 800 in 2 weeks. Today 10% of the company costs about $ 100 billion!
The company was founded in 1999. Attracted investments of $ 25,000,000. At the beginning of 2020, market capitalization exceeded $ 600 billion. $ 100 of investments grew to $ 2.4 million
Sanofi-Synthelabo announced that it has signed an agreement with Pfizer Inc. regarding the divestment of Aventis’ interests in Campto (irinotecan) in response to requests made by the competition authorities.Subject to the success of Sanofi-Synthelabo’s offer for Aventis, Pfizer will take over clinical studies for Campto that are currently conducted by Aventis, together with certain patents and other assets pertaining to territories where Pfizer currently markets irinotecan. The consideration for the whole transaction is of $620 million.
Pfizer Inc. (NYSE:PFE) and Medivation, Inc. (NASDAQ:MDVN) today announced that they have entered into a definitive merger agreement under which Pfizer will acquire Medivation, a biopharmaceutical company focused on developing and commercializing small molecules for oncology, for $81.50 a share in cash for a total enterprise value of approximately $14 billion.
GlaxoSmithKline plc (LSE/NYSE: GSK) and TESARO Inc (NASDAQ: TSRO) today announced that the Companies have entered into a definitive agreement pursuant to which GSK will acquire TESARO, an oncology-focused company based in Waltham, Massachusetts, for an aggregate cash consideration of approximately $5.1 billion (£4.0 billion). The proposed transaction will significantly strengthen GSK’s pharmaceutical business, accelerating the build of GSK’s pipeline and commercial capability in oncology.
NEW YORK & BOULDER, Colo.--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and Array BioPharma Inc. (NASDAQ: ARRY) today announced that they have entered into a definitive merger agreement under which Pfizer will acquire Array, a commercial stage biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule medicines to treat cancer and other diseases of high unmet need. Pfizer has agreed to acquire Array for $48 per share in cash, for a total enterprise value of approximately $11.4 billion. The Boards of Directors of both companies have approved the merger.
Johnson & Johnson
Merck & Co.
Instagram has become a key fixture of Facebook’s growth. Facebook bought the photo-sharing start-up for $1 billion in 2012, paying what seemed like a shocking sum of $1 billion for a company with 13 employees at the time.
February 2014. Facebook has bought messaging app WhatsApp in a deal worth a total of $19bn (£11.4bn) in cash and shares. The deal to buy it includes $4bn in cash and approximately $12bn-worth of Facebook shares, plus an additional $3bn in stock to WhatsApp's founders and employees at a later date.
XRP is the cryptocurrency of the Ripple network. XRP is designed to be a fast and efficient cryptocurrency for cross-border payments. The company has managed to attract investment and attention from Google.Initially, a small project became the basis for the banking systems of Asia, the Middle East, Australia and Canada. After listing on the exchange in 2017, the XRP price was $ 0.006. At the same time, in 2018, Ripple became the main topic of discussion thanks to a fantastic take-off, the basis of which was the trust of the world's financial institutions: at the end of 2017, Ripple was called a “threat to bitcoin”, by the beginning of December 2018, XRP was worth more than $ 3. XRP grew 540 times in 13 months, accounting for 54,000%.
While traditional ICT spending is forecast to broadly track GDP growth over the next decade, the overall industry will be catapulted back to growth of more than 2 x GDP as new technologies begin to account for a larger share of the market. The emergence of IoT is already contributing to overall market growth, and within 5-10 years new technologies such as robotics and AR/VR will also expand to represent a significant and growing share of total ICT spending.
Immunobalm - an immunostimulating drug. Created in the 50s in the USSR by S.E. Chernyshev. In 2012, a group of scientists in Sochi, based on the history of this tool, developed a unique composition of the balm, and it was also strengthened by adding medicinal plants of the Caucasus to the composition of the components. United Financial Group launched the production of RUSICH Balsam in July 2020.
Ingredients: Juglans nigrae pericarpium, Ginkgo bilobae foliorum, Dioscoreae caucasicae rhizomata cum radicibus, Cynarae cardunculi foliorum, Persicae vulgaris cormi, Arctii lappae adices, Sambuci nigrae flores, Laurocerasi officinalis folia, Thujae occidentalis folia, Allii ursinae foliorum, Artemisiae absinthii herbae, Abiei nordmannianae cormi, Petroselini vulgaris herbae, Comari palustris rhizomata cum radicibus.
The main purpose of the drug is to increase human immunity, neutralize viruses and parasitic pathogens, cleanse blood vessels, including brain vessels, remove toxins, toxins, radionuclides and heavy metals, prevent and treat oncology and skin diseases at different stages of their development.
Distinctive properties of Balm: The special qualities of the drug were obtained as a result of combining the achievements of physics, herbal medicine, industrial technology and microbiology.
The combination of plant extract ingredients is selected not only for their medicinal properties, but also for biological compatibility.
The combination of extracts of medicinal ingredients is performed with a cascade enhancement of the basic properties of the drug, due to the simultaneous action of several ingredients.
All ingredients are prepared as concentrates with an extraction ratio of 62%, without the use of preservatives.
The quality of raw materials is ensured by the collection of medicinal plants in the regions of the Caucasian highlands.
Therapeutic effects of Balm: The balm has a high concentration of vitamins, macro and micro elements, enzymes, organic acids, tannins and essential oils, iodine, juglons and polyphenols, which determine the antitumor activity, ginkgolides, which improve the intake of oxygen and nutrients in the organs and facilitate the rapid removal of toxins, which helps expand vessels and increase the elasticity of their walls. The latter is especially important for cerebral vessels.
The likelihood of heart attacks and heart attacks is reduced, the level of bad cholesterol is reduced. Balm contains the most harmless antioxidant in the form of an ingredient in ginkgo biloba. Its flavoglycosides protect the walls of blood vessels from damage by free radicals.
Indications for use: Viral disease. Immunity drop. Oncology. Radionuclide infection. Diabetes. Pancreatitis Gout. Eczema. Neurodermatitis. Prostatitis. Thyroid insufficiency. Inflammation of the female genital area. Ovarian cyst. Pyelonephritis. Urethritis. Cystitis. Mastopathy Adenoma. Myoma.
You can order the balm through an online chat on the website ufgroup.proClose
In 2004 – preclinical trials.
In 2006 - 2007 – clinical trials of the first and second phase.
In 2015 – development of a suppository, a new formula of the drug named FRAN.
What is the difference between FRAN and existing drugs?
The common properties of all chemotherapeutic drugs are high toxicity and a complete lack of selectivity of action, when the drug acts equally on healthy cells of the body and on cancer cells.
The advantage of our project is the uniqueness of the drug. Unlike all other antitumor drugs, FRAN is an absolutely safe drug of natural origin and it does not contain chemical modifiers. This fact determines the unique therapeutic properties of the drug, which will create a very high demand for it in the future.
Research, as well as the opinion of practicing oncologists, suggests that the combination of positive properties makes it unique, without worthy competitors in the antitumor market. This is proved by preclinical trials, clinical trials and more than 500 people who have already been treated with FRAN.
By the sum of the positive qualities combining high antitumor efficacy, absolute selectivity towards tumor cells and complete absence of toxicity, the drug FRAN is unique in comparison with the well-known chemotherapeutic drugs.
The development of the drug FRAN is a revolutionary solution and it opens up a new direction in the science of creating drugs for the safe treatment of cancer and, which is important, it carries out prophylaxis to restore immunity in order to destroy cancer cells at an early stage.
Already, the drug can be ordered by contacting our representatives on our website ufgroup.proClose
Yllo Messenger is a mobile application for instant messaging, crypto assets and business. Decentralized messenger built on cluster architecture. It does not have a central server. In addition to ordinary communication, it has a built-in crypto wallet for storing and transferring various cryptocurrencies
Crypto platform. On the Yllo platform you can issue any digital asset: with a unique name, logo and rules. The issuer himself sets the parameters of the total emission, inflation, burning, commission, distribution, initial price and any other properties of the asset.
Branding. Any element of the platform (instant messenger, notes, wallet for PC) can be branded as a client, as a personal tool based on Yllo.
Cryptocurrency exchange XLT.One - is a platform for the exchange of classic cryptocurrencies and all crypto assets created in Yllo.Close